Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05207514
Other study ID # DPMBC301
Secondary ID
Status Recruiting
Phase Phase 3
First received
Last updated
Start date March 22, 2022
Est. completion date December 2024

Study information

Verified date May 2023
Source Samyang Biopharmaceuticals Corporation
Contact Miryung Jin
Phone +82-2-2157-9842
Email miryung.jin@samyang.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Phase III Clinical Trial to Compare the Efficacy and the Safety of AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Taxotere Versus AC(Doxorubicin, Cyclophosphamide) Followed by 4 Cycles Nanoxel M as Neoadjuvant Chemotherapy in Patients With Breast Cancer


Description:

The purpose of this study is to evaluate efficacy and safety of AC followed by Taxotere versus AC followed by Nanoxel M as neoadjuvant chemotherapy in breast caner patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 320
Est. completion date December 2024
Est. primary completion date March 2024
Accepts healthy volunteers No
Gender Female
Age group 19 Years and older
Eligibility Inclusion Criteria: 1. Patients who voluntarily decide to participate and give written consent after hearing and understanding detailed explanations of this clinical trial 2. Female adult subjects 19 years of age or older 3. Patients who were diagnosed with primary breast cancer by core biopsy 4. Patients who have been identified as HER2 negative in the tissue obtained through core needle biopsy and have confirmed the positive / negative status of ER (Estrogen receptor) and Progesterone receptor (PR) - HER2 positive is defined as IHC 3+ or FISH + 5. Patinets whose TNM stage confirmed by CT or MRI (T2-T3, anyN, M0 or T1-3, N1-3, M0) 6. Patients who show adequate blood, renal, and liver functions at screening as follows <Hematology> - ANC = 2.0 X 109/L - Platelets = 100 X 109/L - Hemoglobin = 10 g/dL (= 6.2 mmol/L) <Liver function> - Total bilirubin < 1.5 X UNL - AST ? ALT = 2.5 X UNL - ALP = 2.5 X UNL <Renal function> - Creatinine < 1.5 X UNL (or creatinine clearance = 60ml/min) 7. Patients whose ECOG performance scores are 0-1 Exclusion criteria: 1. Patients who have distant metastasis 2. Patients who have cystitis or urinary obstruction 3. Patients who have history of thromboembolism or coagulation disorder 4. Patients who have Interstitial lung disease ans liver cirrhosis ( > Child-Pugh class B) 5. Patients who have Insulin-Dependent Type II diabete mellitus 6. Hypertensive Patients who have systolic blood pressure = 160mmHg or diastolic blood pressure = 100mmHg 7. Patients who have received chemotherapy prior to participation in this clinical trial or who have received radiation therapy for breast cancer 8. Patients whose medical or mental state judged by the investigator as to be impossible to understand this clinical study and sign the written consent form 9. Patients who have active infection at the screening visit 10. Patients who have history of grade 2 or higher peripheral motor neuropathy or peripheral sensory neuropathy by CTCAE V5.0 11. Pregnant or lactating women 12. A woman of childbearing age who does not agree to the use of medically acceptable contraceptive methods (blocking, intrauterine contraceptive devices) during the study (However, those who have a record of menopause before definition (defined as amenorrhea for at least one year) or surgical sterilization are excluded from women of childbearing age..) 13. Patients who have a history of malignant tumors except breast cancer within 5 years of screening visit 14. Patients who have heart failure (NYHA class I or higher), arrhythmias requiring treatment, and clinically significant heart valve disease 15. Patients who have transient cerebral ischemic attack (TIA), myocardial infarction, unstable angina, cerebral infarction, cerebral hemorrhage within 6 months prior to screening or a history of angioplasty or coronary artery bypass surgery 16. Patients who have history of anaphylaxis to the main or subcomponents of this ingredient 17. Patients requiring the administration of concomitant contraindications during this clinical trial 18. Patients who are contraindicated in the administration of corticosteroids 19. Patients who have experience of participating in another clinical trial within 3 months to screening (participation is based on the date of final administration of the investigational drug) 20. Other, if the investigator judges that he or she is not suitable to participate

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Nanoxel M
75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
Taxotere
75 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
Doxorubicin
60 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with cyclophosphamide
Cyclophosphamide
600 mg/m2, intravenously every 3 weeks for 4 cycles. Given as first treatment with doxorubicin.

Locations

Country Name City State
Korea, Republic of Sevrance Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Samyang Biopharmaceuticals Corporation

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Pathological complete response (pCR) rate using the definition of ypT0/Tis ypN0 H & E staining of tissues obtained from breast and axillary lymph nodes was defined as the absence of invasive cancer, and the proportion of subjects was determined. at the time of definitive surgery
Secondary Percentage of ypT0 Subjects H & E staining of tissues obtained from breast was defined as the absence of invasive and in situ cancer, and the proportion of subjects was determined. at the time of definitive surgery
Secondary Percentage of ypT0/is Subjects H & E staining of tissues obtained from breast was defined as the absence of invasive cancer, and the proportion of subjects was determined. at the time of definitive surgery
Secondary Percentage of ypT0 ypN0 Subjects H & E staining of tissues obtained from breast and axillary lymph nodes was defined as the absence of invasive and in situ cancer, and the proportion of subjects was determined. at the time of definitive surgery
Secondary Response rate Response rate confirmed by CT or MRI during the study (by RECIST 1.1) at the time of definitive surgery
Secondary Percentage of Subjects with Breast Conservation Surgery Percentage of Subjects with Breast Conservation Surgery at the time of definitive surgery
Secondary Percentage of subjects by RCB (Residual cancer burden) grade after chemotherapy before surgery tissue obtained from breat and axillary lymph node were evaluated to determine the proportion of subjects in each grade (RCB 0, RCB-I, RCB-II, RCB III) at the time of definitive surgery
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A